S&P Futures
5,885.50 -10.75 (-0.18%) Dow Futures
43,110.00 -67.00 (-0.16%) Nasdaq Futures
20,467.50 -52.00 (-0.25%) Russell 2000 Futures
2,248.80 -6.70 (-0.30%) Crude Oil
70.43 -0.13 (-0.18%) Gold
2,747.50 +8.60 (+0.31%)
Peak Bio, Inc. (PKBO)
| Previous Close | 0.0000 |
| Open | 0.0500 |
| Bid | 0.0230 x 800 |
| Ask | 0.3000 x 4000 |
| Day's Range | 0.0500 - 0.0700 |
| 52 Week Range | 0.0020 - 0.2650 |
| Volume | |
| Avg. Volume | 2,001 |
| Market Cap | 1.619M |
| Beta (5Y Monthly) | 1.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1800 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireAkari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger
BOSTON and LONDON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the effectiveness of the Form S-4, originally filed with the SEC on September 13, 2024 related to the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. The Form S-4 was declared effective by the SEC on October 11, 2024 allowing the Company to definitively schedule the Gen
- GlobeNewswire
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics
BOSTON and LONDON, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the appointment of Rob Bazemore, experienced life sciences leader, to the Akari Board of Directors effective September 17, 2024. “I am very honored to have the opportunity to work with this distinguished board of directors to advance the portfolio opportunities,” said Mr. Bazemore. “Focu
